Paper Title
TRANEXAMIC ACID (TXA)- AND MEFENAMIC ACID: An Overviewâ€,
Article Identifiers
Authors
Dr.D.NAGAVALLI , P.NANTHAGOPAL
Keywords
HMB, Tranexamic Acid, Mefenamic Acid, Antifibrinolytic agent. Introduction:
Abstract
The entire world has come major problem is facing on puberty womens for entier life cycle,involved in Common causes for Heay bleeding (periods) is termed is called-Menorrhagia , grappling with a common enemy in womens Menstrual cycles. The Heavy or prolonged vaginal bleeding.( HMB-Heavy Menstrual Bleeding) has menstrual period with excessively heavy blood flow.Abnormal utrine bleeding can be caused by strctural abnormalities in reproductive tract, anovulation, bleeding disorders, hormonal issues (hypothyroidism) or cancer of the reproductive tract.Tougher challenge leading to millions of cases and a staggering number of patients is affected in Anemic condition. Tranexamic Acid and Mefenamic Acid is an FDA-approved and sold under the oral administration for (NSAIDS and Antifibrinolytics) drug for use in Puberty womens for during heavy bleeding in menstrual cycle. Tranexamic Acid is a prevents the breakdown of blood clots to control excessive bleeding during periods. Mefenamic acid is also blocks the production of certain chemical messengers that cause pain and inflammation, Tranexamic acid blocks the activity one of the specific for preventing fibrin degradation , Tranexamic acid has a eight times the antifibrinolytic activity of an older analogue, aminocarproic acid. It is together Tranexamic Acid and Mefenamic acid is used for treatement of heavy menstrual bleeding and acute pain that occurs with menstrual disorders. According to the study conducted, it was found that when was given alone in the patient suffering from HMB with acute pain symptoms, the mean recovery was 87.3% and mortality rate was 69.34% Trapic-MF significantly reduces the heay and mortality and shows more safety,efficacy and reduced serious adverse effects by absolute 8% and no significant Grade 3 or 4 adverse effects were reported. When Tranexamic Acid was given in combination with Mefenamic acid was superior to Tranexamic acid alone in reducing recovery (65.5%) and accelerating improvement in clinical status among patients with heavy bleeding and pain, notably among those receiving problems. The mortality rate for Mefenamic acid in combination with Tranexamic acid , a relative reduction of 35%. Adverse events and serious adverse events were reported in 41% and 15% of patients treated with Mefenamic acid in combination with Tranexamic acid, respectively, vs. 48% and 20% in patients treated with Tranexamic acid.
Downloads
How To Cite (APA)
Dr.D.NAGAVALLI & P.NANTHAGOPAL (April-2023). TRANEXAMIC ACID (TXA)- AND MEFENAMIC ACID: An Overviewâ€,. INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT, 8(4), a594-a608. https://ijnrd.org/papers/IJNRD2304074.pdf
Issue
Volume 8 Issue 4, April-2023
Pages : a594-a608
Other Publication Details
Paper Reg. ID: IJNRD_188653
Published Paper Id: IJNRD2304074
Downloads: 000121986
Research Area: Health ScienceÂ
Country: Kancheepuram, TAMIL NADU, India
Published Paper PDF: https://ijnrd.org/papers/IJNRD2304074.pdf
Published Paper URL: https://ijnrd.org/viewpaperforall?paper=IJNRD2304074
About Publisher
Journal Name: INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT(IJNRD)
ISSN: 2456-4184 | IMPACT FACTOR: 8.76 Calculated By Google Scholar | ESTD YEAR: 2016
An International Scholarly Open Access Journal, Peer-Reviewed, Refereed Journal Impact Factor 8.76 Calculate by Google Scholar and Semantic Scholar | AI-Powered Research Tool, Multidisciplinary, Monthly, Multilanguage Journal Indexing in All Major Database & Metadata, Citation Generator
Publisher: IJNRD (IJ Publication) Janvi Wave | IJNRD.ORG | IJNRD.COM | IJPUB.ORG
Licence
This work is licensed under a Creative Commons Attribution 4.0 International License and The Open Definition
Publication Timeline
Article Preview: View Full Paper
Call For Paper
IJNRD is a Scholarly Open Access, Peer-reviewed, and Refereed Journal with a High Impact Factor of 8.76 (calculated by Google Scholar & Semantic Scholar | AI-Powered Research Tool). It is a Multidisciplinary, Monthly, Low-Cost Journal that follows UGC CARE 2025 Peer-Reviewed Journal Policy norms, Scopus journal standards, and Transparent Peer Review practices to ensure quality and credibility. IJNRD provides indexing in all major databases & metadata repositories, a citation generator, and Digital Object Identifier (DOI) for every published article with full open-access visibility.
The INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT (IJNRD) aims to advance applied, theoretical, and experimental research across diverse fields. Its goal is to promote global scientific information exchange among researchers, developers, engineers, academicians, and practitioners. IJNRD serves as a platform where educators and professionals can share research evidence, models of best practice, and innovative ideas, contributing to academic growth and industry relevance.
Indexing Coverage includes Google Scholar, SSRN, ResearcherID-Publons, Semantic Scholar (AI-Powered Research Tool), Microsoft Academic, Academia.edu, arXiv.org, ResearchGate, CiteSeerX, ResearcherID (Thomson Reuters), Mendeley, DocStoc, ISSUU, Scribd, and many more recognized academic repositories.
How to submit the paper?
By Our website
Click Here to Submit Paper Online
Important Dates for Current issue
Paper Submission Open For: October 2025
Current Issue: Volume 10 | Issue 10 | October 2025
Impact Factor: 8.76
Last Date for Paper Submission: Till 31-Oct-2025
Notification of Review Result: Within 1-2 Days after Submitting paper.
Publication of Paper: Within 01-02 Days after Submititng documents.
Frequency: Monthly (12 issue Annually).
Journal Type: IJNRD is an International Peer-reviewed, Refereed, and Open Access Journal with Transparent Peer Review as per the new UGC CARE 2025 guidelines, offering low-cost multidisciplinary publication with Crossref DOI and global indexing.
Subject Category: Research Area
Call for Paper: More Details
